StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) KPIs and segments

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.88+0.06 (+1.57%)

Close on Nov 16, 2026Market cap $558.30MP/E 26.4Yield –

KPIs & segments

Operating metrics and segments that drive Anbio Biotechnology's business

Anbio Biotechnology's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
FY2025
FY2024
FY2023
FY2022
European Union($M)
5.155.624.6620.3
Asia Pacific($M)
1.520.510.073.19
Other Regions($M)
1.410.470.11
North America($M)
0.300.110.220.05
South America($M)
0.271.481.65

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-04-07.

See a number that looks wrong?